Company Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
28.93 USD +1.58% Intraday chart for Protagonist Therapeutics, Inc. +0.17% +26.17%

Business Summary

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

Number of employees: 112

Sales per Business

USD in Million2022Weight2023Weight Delta
Peptide-based Therapeutics
100.0 %
27 100.0 % 60 100.0 % +125.73%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
27 100.0 % 60 100.0 % +125.73%

Managers

Managers TitleAgeSince
Chief Executive Officer 67 08-11-30
Director of Finance/CFO 50 22-04-17
Chief Tech/Sci/R&D Officer - 17-06-30
Chief Tech/Sci/R&D Officer 69 18-05-23
Chief Tech/Sci/R&D Officer 65 22-11-06
General Counsel - -
Human Resources Officer - -
Corporate Officer/Principal 66 19-01-16
Corporate Officer/Principal - 16-12-31
Corporate Officer/Principal 52 18-08-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 74 17-06-07
Chairman 69 09-01-31
Director/Board Member 61 23-10-25
Chief Executive Officer 67 08-11-30
Director/Board Member 74 20-08-11
Director/Board Member 66 16-06-30
Director/Board Member 48 18-05-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 58,274,998 56,809,066 ( 97.48 %) 0 97.48 %

Shareholders

NameEquities%Valuation
BVF, Inc.
9.858 %
5,744,848 9.858 % 175 M $
Farallon Capital Management LLC
9.840 %
5,734,430 9.840 % 174 M $
RTW Investments LP
9.121 %
5,315,514 9.121 % 161 M $
BlackRock Advisors LLC
9.019 %
5,255,910 9.019 % 160 M $
Vanguard Fiduciary Trust Co.
5.412 %
3,153,916 5.412 % 96 M $
2,729,929 4.685 % 83 M $
Point72 Asset Management LP
4.485 %
2,613,453 4.485 % 79 M $
Johnson & Johnson Innovation - JJDC, Inc.
4.203 %
2,449,183 4.203 % 74 M $
Kynam Capital Management LP
3.440 %
2,004,875 3.440 % 61 M $
Adage Capital Partners GP LLC
2.217 %
1,291,701 2.217 % 39 M $

Company contact information

Protagonist Therapeutics, Inc.

7707 Gateway Boulevard Suite 140

94560-1160, Newark

+

http://www.protagonist-inc.com
address Protagonist Therapeutics, Inc.(PTGX)